anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The anatomical location for lateral ligament reconstruction remains a significant challenge. With the development of arthroscopic technology, arthroscopic-assisted lateral ligament reconstruction can significantly facilitate the correct localization of anatomical points. However, there is limited evidence on the clinical efficacy of arthroscopic ligament reconstruction compared with percutaneous ligament reconstruction.
METHODS: This study included 72 patients who underwent lateral ligament reconstruction for chronic lateral ankle instability from 2018 to 2022. The follow-up duration in the percutaneous(n = 35) and the arthroscopic(n = 37) groups was 6-30 months. The patients were evaluated before the operation, at 6 months after surgery, and at the final follow-up. The American Orthopaedic Foot and Ankle Society score (AOFAS), Karlsson-Peterson score, and Visual Analog Scale (VAS) were evaluated at each time point. The complications and the time required to return to sports were documented during the follow-up.
RESULTS: All clinical evaluations significantly improved after surgery in both groups. There was no significant difference between the two groups in the AOFAS score, VAS score, and complications. The Karlsson-Peterson score (85.4 vs 83.6, p = 0.044), surgical duration (50.4 min vs 60.2 min, p < 0.001), and time to return to sports (17.8 weeks vs 20.5 weeks, p = 0.033) were all improved in the arthroscopic group.
CONCLUSION: Satisfactory clinical outcomes can be achieved through both arthroscopic and percutaneous anatomic ligament reconstruction. The ligament remnant and anatomical localization point can be observed directly by using an arthroscope. Arthroscopic ligament reconstruction can be a more viable alternative for patients with chronic ankle instability due to its minimal disturbance to the stump of the ligament and reduced operative aggression.
This invention provides processes for producing quinolone compounds which comprise cultivating Amycolata sp. FERM BP-4785, and then isolating quinolone compounds from the fermentation broth. The compounds produced by these processes include compounds of formula (I) wherein R1 is H, R2 is (a) and R3 is CH¿3; R?1 is CH¿3, R?2 is (a) and R3 is CH¿3?; or R?1¿ is CH¿3, R?2 is (b) and R3 is CH¿3?; and the like. The present invention also relates to a pharmaceutical composition comprising the same, which is useful in the treatment of diseases, disorders and adverse conditions caused by Helicobacter pylori and is particularly useful in the treatment of gastroduodenal disorders, diseases and adverse conditions caused thereby.
Omeprazole is a highly effective drug for the treatment of gastroesophageal reflux disease (GERD) in infants. Infants, aged 0-12 months, require a non-standard dose of omeprazole. Due to this fact extemporaneous formulations of omeprazole are administered to these infants. The oral bioavailability of omeprazole in nonproprietary formulations may be unpredictable and produce variable degrees of drug exposure. The dose range for GERD management in pediatric studies using omeprazole is 0.3 - 3.5 mg/kg/day.

Dosing information, aged-specific pharmacodynamic and pharmacokinetic data are not available in infants, aged 0-12 months. Two adult studies at healthy volunteers suggest that an omeprazole suppository is an effective dosage form.This study is designed to evaluate and to compare the efficacy, the pharmacodynamics and the pharmacokinetics of oral and rectal omeprazole treatment in infants with gastroesophageal reflux disease.
BACKGROUND: In the process of finding the causative variant of rare diseases, accurate assessment and prioritization of genetic variants is essential. Previous variant prioritization tools mainly depend on the in-silico prediction of the pathogenicity of variants, which results in low sensitivity and difficulty in interpreting the prioritization result. In this study, we propose an explainable algorithm for variant prioritization, named 3ASC, with higher sensitivity and ability to annotate evidence used for prioritization. 3ASC annotates each variant with the 28 criteria defined by the ACMG/AMP genome interpretation guidelines and features related to the clinical interpretation of the variants. The system can explain the result based on annotated evidence and feature contributions.
RESULTS: We trained various machine learning algorithms using in-house patient data. The performance of variant ranking was assessed using the recall rate of identifying causative variants in the top-ranked variants. The best practice model was a random forest classifier that showed top 1 recall of 85.6% and top 3 recall of 94.4%. The 3ASC annotates the ACMG/AMP criteria for each genetic variant of a patient so that clinical geneticists can interpret the result as in the CAGI6 SickKids challenge. In the challenge, 3ASC identified causal genes for 10 out of 14 patient cases, with evidence of decreased gene expression for 6 cases. Among them, two genes (HDAC8 and CASK) had decreased gene expression profiles confirmed by transcriptome data.
CONCLUSIONS: 3ASC can prioritize genetic variants with higher sensitivity compared to previous methods by integrating various features related to clinical interpretation, including features related to false positive risk such as quality control and disease inheritance pattern. The system allows interpretation of each variant based on the ACMG/AMP criteria and feature contribution assessed using explainable AI techniques.
The invention provides a method for harvesting viruses by utilization of a harvest solution with high osmotic pressure. The osmotic pressure of the provided harvest solution with high osmotic pressure is 1500-2500mOs mol/kg. The harvest solution comprises a cell buffer PBS and cane sugar, and can lyse cells efficiently. Viruses in the cells can be released and collected effectively. The method is a new virus harvesting way, and breaks down barriers caused by limitation of harvest technologies in large-scale plate culture virus technologies. The technology method for harvesting viruses through a way of changing cell osmotic pressure has simple operation, is convenient for large-scale production, can raise industrialization capability effectively, is suitable for large-scale production of enterprises, and has strong practicality. The provided harvest solution comprises cane sugar only, and can ensure the safety of the products effectively.
The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
PURPOSE:To provide a cosmetic having high oxidation stability, giving refreshing feeling to the skin, and free from oil odor of decomposed components, by using sal fat obtained by the extraction of the seed of sal tree and/or its hydrogenated product as an essential component. CONSTITUTION:The seed of sal tree is crushed and extracted with hexane, and the obtained sal fat and/or its hydrogenated product is used as an essential component of the objective cosmetic. Although sal fat has a triglyceride structure similar to other vegetable oils, it has excellent oxidation stability because the unsaturated fatty acid accounting for 40% of the fat is mostly oleic acid. The saturated fatty acids existing in the fat are palmitic acid, stearic acid and arachic acid, and accordingly, it has advantages in view of stability and odor. Sal fat is solid at normal temperature; however, it melts rapidly on the skin because of its low melting point, i.e. 30-35 deg.C.
PROBLEM TO BE SOLVED: To obtain a detergent compsn. which has improved bactericidal action, detergency, and feeling in use and is excellent in usability by filling a compsn. contg. a specified amt. of water, a bactericide having cationic static charge, and a surfactant into a foamer container in which the compsn. is pressurized to be mixed with air and which discharges the compsn. as a foam through a frothing member having many small holes and then a discharge port. SOLUTION: This compsn. contains 50 wt.% or higher, pref. 70-97 wt.%, water and has a viscosity of 0.1-10 cP at 25 deg.C. Pref., the average bubble size of a foam ejected from the foamer container is 0.5 mm or lower. Based on the compsn., the bactericide is compounded pref. in an amt. of 0.05-3 wt.%, and the surfactant, pref. in an amt. of 1-10 wt.%. Water is compounded in a wt. of 5-90 times that of the surfactant.
Polygenic risk scores (PRS) estimate an individual's genetic risk for a disease or trait compared to a matched population. For many rheumatic diseases PRS have been developed that have discriminatory capacity better than some widely used biomarkers, and in some cases are the most discriminatory tests available. These PRS assessments do not rely on the disease being present or its activity level, making them highly valuable for predicting disease development or enabling early diagnosis. However, most PRS to date have been developed in research settings, and in populations of European-ancestry. Further studies are required to assess their utility in clinical settings, in relation to existing tests, and in non-European populations. Such studies are underway, and it is likely in the near future these tests will become widely available, with significant benefits for the practice of medicine.
The concept of care bundle; It was developed by the American Institute for Healthcare Improvement (IHI) in 2001 to provide the best care safely in order to achieve desired results in patient care, increase compliance with standard procedures, improve patient safety and quality of care. Ensuring that nurses perform gastrostomy care correctly and according to the guidelines published in international standards will minimize the development of problems that may arise in gastrostomy care.

Method: The research was planned as a mixed type research design in order to development and implementation the gastrostomy care bundle for gastrostomy care. The study was planned to be carried out in Hacettepe University Adult Hospital Brain and neurosurgery intensive care unit between September 2021 and September 2022. In the quantitative phase of the research; The development of the gastrostomy care bundle will be carried out using the care bundle development approach in line with the recommendations of the Institute for Healthcare Improvement (IHI) and expert opinions will be taken. Nurses working in the brain and neurosurgery intensive care unit will be trained on the gastrostomy care bundle and will be expected to practice care bundle. Before the training, nurses will be asked to fill in the "Nurse Introductory Information Form", "Evidence-Based Attitude Scale towards Nursing" and "Gastrostomy Care Questionnaire (pre-test)". The nurse population of the research will consist of 14 nurses working in the brain and neurosurgery intensive care unit. At this stage, the sample selection will not be made, and it will be tried to reach all of the working nurses. The "Gastrostomy Care bundle" form will be used by the nurses in the gastrostomy care in the brain and Neurosurgery intensive care unit between September 2021 and September 2022 , which is determined for the patient sample. Nurses' compliance with the care bundle will be evaluated by the researcher with the "Gastrostomy Care Bundle Compliance Evaluation Control Form" by making daily visits to the intensive care unit. At the end of the period determined for the use of the care bundle in the intensive care unit, the nurses will be asked to fill in the "Evidence-Based Attitude Scale towards Nursing" and "Gastrostomy Care Questionnaire (post-test)". In the qualitative phase of the research, nurses working in the brain and neurosurgery intensive care unit will be interviewed about their experiences with the use of gastrostomy care bundle. At the end of the study, nurses' compliance with the use of care bundle, the effect of gastrostomy care bundle use/gastrostomy education on nurses' knowledge levels and attitudes towards evidence-based nursing, and nurses' views on gastrostomy care bundle will be evaluated.
The present invention relates to a traditional Chinese medicine capsule and a preparation method thereof, particularly to a capsule for treating myocarditis of coxsackie B virus type, and a preparation method thereof. The present invention has the technical scheme that American ginseng and radish seed are compatible and are used for making the capsule for treating myocarditis of coxsackie B virus type. The made capsule simultaneously contains traditional Chinese medicine components of American ginseng and radish seed, and is also added with cowherb seed, schisandra, lilyturf root, cortex moutan and milk vetch. The weight percentage of components of the traditional Chinese medicine is shown in the following: 15 to 30% of American ginseng, 5 to 15% of radish seed, 4 to 10% of cowherb seed, 4 of 15% schisandra, 5 to 20% of ophiopogon root, 10 to 25% of cortex moutan and 30 to 40% of milk vetch. The present invention has the characteristics of stable curative effect, convenient administration, novel therapeutic scheme, etc. The present invention breaks through the contraindication of medicine compatibility of American ginseng and radish seed, and has obvious effects for treating myocarditis of coxsackie B virus type, and the total effective rate of clinic treatment is 85%.
A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80～120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
Renal: About one of 100 patients developed proteinuria (see WARNINGS).

Each of the following has been reported in approximately 1 to 2 of 1000 patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria, and urinary frequency.

Hematologic: Neutropenia/agranulocytosis has occurred (see WARNINGS). Cases of anemia, thrombocytopenia, and pancytopenia have been reported.

Dermatologic: Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about 4 to 7 (depending on renal status and dose) of 100 patients, usually during the first four weeks of therapy. It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction, short-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about 2 of 100 patients. Between 7 and 10 patients with skin rash have shown an eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported.

Flushing or pallor has been reported in 2 to 5 of 1000 patients.

Cardiovascular: Hypotension may occur; see WARNINGS and PRECAUTIONS: Drug Interactions for discussion of hypotension with captopril therapy.

Tachycardia, chest pain, and palpitations have each been observed in approximately 1 of 100 patients.

Angina pectoris, myocardial infarction, Raynaud’s syndrome and congestive heart failure have each occurred in 2 to 3 of 1000 patients.

Dysgeusia: Approximately 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception. Taste impairment is reversible and usually self-limited (2 to 3 months) even with continued drug administration. Weight loss may be associated with the loss of taste.

Angioedema: Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in 1000 patients. Angioedema involving the upper airways has caused fatal airway obstruction. (See WARNINGS: Head and Neck Angioedema, Intestinal Angioedema and PRECAUTIONS: Information for Patients.)

Cough: Cough has been reported in 0.5 to 2% of patients treated with captopril in clinical trials (see PRECAUTIONS: General: Cough).

The following have been reported in about 0.5 to 2 percent of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials; gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias.
BACKGROUND: It can be challenging to perform activities of daily living in patients with chronic neck pain. As the severity of the pain increases, the quality of the movements decreases. Not only the neck, but also the shoulder, elbow, grip strength and psychomotor skills are affected by these pains.
OBJECTIVE: In this study, it was aimed to investigate the effect of neck pain on grip strength and psychomotor skills in adults diagnosed with chronic neck pain.
METHODS: A cross-sectional study was conducted to examine the effect of pain on grip strength and psychomotor skills in patients with chronic neck pain. This study was planned to be carried out between October 2019 and May 2020 at the Private Yaşam Medical Center in Adana, with the official permission of the institution manager, but this period was carried out between October 2019 and November 2020 due to the fact that sufficient number of patients could not be reached due to the COVID-19 global epidemic. A total of 80 individuals, including 40 control and 40 patients, were included in the study. Forty adult patients who applied to the clinic with a diagnosis of chronic neck pain and 40 healthy adults without a diagnosis of chronic neck pain were included in the study. Conducted with 80 adults between the age of 19 and 74 years old. Individuals were divided into Group 1-control group (n = 40) and Group 2-patient group (n = 40). Information such as age, height, body weight and occupation of the groups were noted. Visual analogue scale and Neck Disability Index were applied to both the groups; hand grip strength with a Jamar hydraulic hand dynamometer, finger lateral grip strength with a pinchmeter and psychomotor skills with the Purdue Pegboard test were evaluated.
RESULTS: In the study, hand grip strength (p < .05), finger lateral grip strength (p < .05), psychomotor skills (p < .01) showed a statistically significant decrease in the patient group compared to the control group.
CONCLUSION: It is thought that in addition to the routine treatments for neck pain in the treatment plan of patients with chronic neck pain, exercises to improve the functionality and psychomotor skills in daily living activities can be included in the direction of increasing the grip strength and will guide future studies.
Sepsis is a common life-threatening disease caused by dysregulated immune response and metabolic acidosis which lead to organ failure. An abnormal expression of aquaporins plays an important role in organ failure. Additionally, genetic variants in aquaporins impact on the outcome in sepsis. Thus, we investigated the polymorphism (rs17553719) and expression of aquaporin-3 (AQP3) and correlated these measurements with the survival of sepsis patients. Accordingly, we collected blood samples on several days (plus clinical data) from 265 sepsis patients who stayed in different ICUs in Germany. Serum plasma, DNA, and RNA were then separated to detect the promotor genotypes of AQP3 mRNA expression of AQP3 and several cytokines. The results showed that the homozygote CC genotype exhibited a significant decrease in 30-day survival (38.9%) compared to the CT (66.15%) and TT genotypes (76.3%) (p = 0.003). Moreover, AQP3 mRNA expression was significantly higher and nearly doubled in the CC compared to the CT (p = 0.0044) and TT genotypes (p = 0.018) on the day of study inclusion. This was accompanied by an increased IL-33 concentration in the CC genotype (day 0: p = 0.0026 and day 3: p = 0.008). In summary, the C allele of the AQP3 polymorphism (rs17553719) shows an association with increased AQP3 expression and IL-33 concentration accompanied by decreased survival in patients with sepsis.
Adult participants will receive investigator's choice of SOC MKI therapy with either 140 mg cabozantinib PO QD or 300 mg vandetanib PO QD in 28-day cycles. Adolescents participants (≥ 12 and \< 18 years of age) will receive vandetanib, PO QD or every other day, in 28-day cycles depending on the body surface area (BSA), at a dose determined according to the dosing nomogram available in the E.U. Vandetanib SmPC.
NEW MATERIAL:The 9-nitrocamptothecin of formula. USE:Intermediate for the synthesis of various 9-substituted camptothecin derivatives useful as carcinostatic agents, etc. PROCESS:Camptothecin is dissolved in concentrated sulfuric acid, and concentrated nitric acid is added slowly to the solution under ice cooling. The amount of the nitric acid is several times equivalent based on camptothecin. The mixture is stirred and made to react at room temperature for 24-72hr, and the produced reaction liquid is poured into water and extracted with chloroform. The chloroform layer is dried with anhydrous magnesium sulfate, the solvent is evaporated to dryness in vacuum, and the residue is separated and purified by silica gel chromatography.
SERIOUS INFECTIONS

Patients treated with adalimumab products, including CYLTEZO, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CYLTEZO if a patient develops a serious infection or sepsis. 

Reported infections include:

  * Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CYLTEZO use and during therapy. Initiate treatment for latent TB prior to CYLTEZO use. 
  * Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. 
  * Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. 



Carefully consider the risks and benefits of treatment with CYLTEZO prior to initiating therapy in patients with chronic or recurrent infection. 

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CYLTEZO, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2)].